Migraine sufferers who are not able to react to existing treatment could finally put an end to their sufferings with a new drug expected to hit the market in the near future.
Existing migraine drugs such as triptans are not always effective among at least a third of migraine patients and are dangerous for those who also suffer from heart problems. However the new drug, called as telcagepant, currently being developed does not have the same side effects as the triptans drugs and can be safely used by heart patients.
Professor Lars Edvinsson, of University Hospital in Lund, revealed that the drug blocks calcitonin-gene-related peptide in the central nervous system which helps alleviate the pain.
In a report published in the magazine The Lancet, the researchers revealed some of the side effects of the drug which includes dry mouth, dizziness, nausea, fatigue, and drowsiness. "The clinical trials we have reviewed provide evidence that CGRP receptors are important molecular targets for development of anti-migraine drugs", the report added.